Please login to the form below

Not currently logged in
Email:
Password:

CAR-T therapies

This page shows the latest CAR-T therapies news and features for those working in and with pharma, biotech and healthcare.

Gilead’s CAR-T cell therapy recommended by NICE for lymphoma

Gilead’s CAR-T cell therapy recommended by NICE for lymphoma

Yescarta is the first CAR T-cell therapy recommended for routine use on the NHS. ... Dr Véronique Walsh, vice president and general manager, Gilead Sciences UK &Ireland said: “This news comes at a time when new hospitals are preparing to deliver CAR

Latest news

More from news
Approximately 4 fully matching, plus 97 partially matching documents found.

Latest Intelligence

  • ASH 2022: bad blood but big advances ASH 2022: bad blood but big advances

    CAR-T is offering an improvement on invasive stem cell therapy, manipulating cells to hunt down and kill cancer cells. ... Multiple myeloma was a major focus, with data presentations on emerging and approved bispecific antibodies and CAR-T therapies

  • CAR-T cell therapy in oncology CAR-T cell therapy in oncology

    Managing the complexities of current generation CAR-T therapies. While the potential of CAR-T therapies is extraordinary, the complexity and cost of their supply chains jeopardise scalability and long-term ... Today there is research using allogeneic

  • Charting patient pathways with precision for better healthcare Charting patient pathways with precision for better healthcare

    more as many of the parts don’t mesh together, are fitted at different times and operate across a crowded spectrum. ... We will see faster progress in areas such as CAR-T and gene therapies because these are personalised medicines and the patient is

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    Historically, both large pharmaceutical and small biotechnology companies have relied on both internal and external sourcing of innovative and promising therapies. ... and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers

  • The impact of COVID-19 on clinical trials The impact of COVID-19 on clinical trials

    impact on the initiation and completion of hundreds of clinical trials involving investigational therapies for many serious diseases. ... Therapy mechanism of action – immunosuppressive therapies and therapies that require complex and prolonged

More from intelligence
Approximately 0 fully matching, plus 29 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • White paper: Are we prepared for the influx of CAR-Ts?

    Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies. ... With CAR-Ts continuing to take centre stage as a paradigm shift in the treatment of cancer

  • The heavy toll of COVID-19 on cancer patients

    For example, all CAR-T cell therapies were paused as intensive care unit beds were needed to help COVID-19 patients recover. ... New therapies that minimize hospital visits may have to be prioritized by pharmaceuticals and MedTech companies.

  • In the precision medicine era, the line between products and services is blurred

    Instead, we carried out in-depth interviews with different types of stakeholders who had considerable experience working on early CAR-T therapies and clinical trials. ... Both of these scenarios were true in the case of the CAR-T treatment.

  • Precision paediatrics: Treating patients with CAR-T

    It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach. ... This approach can make targeted therapies like CAR-T a reality. A good example at GOSH is in bone marrow transplants.

  • Highlights in haematologic malignancy from ASH 2018

    However, CAR T-cell therapies stop working in some patients and severe toxicity can also occur. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...